ELAN — Elanco Animal Health Incorporated

Summary of Elanco Animal Health Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $1.371 billion, a 15% increase year-over-year; 10% organic constant currency growth.
• Adjusted EBITDA: $334 million, up 21% from the previous year.
• Adjusted EPS: $0.40, an 8% increase year-over-year.
• Gross Margin: 57%, a slight decrease of 40 basis points due to inflation and inventory costs.
• Net Debt: $3.3 billion with a net leverage ratio of 3.5x, with a target to reduce to below 3x by 2027.

2. Strategic Updates and Business Highlights:

• Strong performance across all major geographies and species, with notable growth in U.S. Pet Health (6% growth) and Farm Animal (15% growth).
• Significant innovation revenue of $287 million in Q1, leading to an increased full-year innovation target of $1.2 billion.
• Key products like Zenrelia and Credelio Quattro are driving market share gains in both the U.S. and international markets.
• Successful expansion into new retail partnerships with Costco and Dollar General, contributing to high single-digit growth in the OTC business.
• Elanco Ascend initiative is expected to enhance operational efficiencies and margins, with over 5,000 projects logged.

3. Forward Guidance and Outlook:

• Full-year organic constant currency growth guidance raised to 5% to 7%, up from 4% to 6%.
• Adjusted EBITDA guidance increased to $975 million to $1.005 billion.
• Adjusted EPS guidance raised to $1.03 to $1.09.
• Anticipated acceleration in U.S. Pet Health growth in the second half of 2026, driven by new product launches and corporate account growth.

4. Bad News, Challenges, or Points of Concern:

• Gross margin pressures are expected to continue in the near term due to inflation and product mix.
• Competitive pressures from generics and other market entrants are acknowledged, with potential impacts on pricing and volume.
• The FDA has requested additional data for Zenrelia’s label update, which may delay further market potential.
• The company is cautious about consumer spending trends impacting vet visits, although it does not anticipate this affecting overall growth.

5. Notable Q&A Insights:

• Management noted that January and February were impacted by cooler weather, but a strong recovery was observed in March and April.
• Corporate accounts are growing, with a focus on value-based approaches rather than price competition.
• Zenrelia's success is attributed to its efficacy and growing market share, despite existing label restrictions.
• The company is committed to reinvesting in innovation while maintaining a focus on operational efficiencies through Elanco Ascend.
• Future M&A activity is expected to be limited to small tuck-in acquisitions, with a focus on maintaining financial discipline and reducing leverage.

Overall, Elanco demonstrated strong growth and innovation momentum in Q1 2026, with a positive outlook for the remainder of the year, although challenges related to margins and competitive pressures remain.